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Abstract
 
CD4
 
 
 
CD25
 
 
 
 T cells have been identified as a population of immunoregulatory T cells, which
mediate suppression of CD4
 
 
 
CD25
 
 
 
 T cells by cell–cell contact and not secretion of suppres-
sor cytokines. In this study, we demonstrated that CD4
 
 
 
CD25
 
 
 
 T cells do produce high levels
of transforming growth factor (TGF)-
 
 
 
1 and interleukin (IL)-10 compared with CD4
 
 
 
CD25
 
 
 
T cells when stimulated by plate-bound anti-CD3 and soluble anti-CD28 and/or IL-2, and se-
cretion of TGF-
 
 
 
1 (but not other cytokines), is further enhanced by costimulation via cyto-
toxic T lymphocyte–associated antigen (CTLA)-4. As in prior studies, we found that
CD4
 
 
 
CD25
 
 
 
 T cells suppress proliferation of CD4
 
 
 
CD25
 
 
 
 T cells; however, we observed
here that such suppression is abolished by the presence of anti–TGF-
 
 
 
. In addition, we found
that CD4
 
 
 
CD25
 
 
 
 T cells suppress B cell immunoglobulin production and that anti–TGF-
 
 
 
again abolishes such suppression. Finally, we found that stimulated CD4
 
 
 
CD25
 
 
 
 T cells but
not CD4
 
 
 
CD25
 
 
 
 T cells express high and persistent levels of TGF-
 
 
 
1 on the cell surface.
This, plus the fact that we could find no evidence that a soluble factor mediates suppression,
strongly suggests that CD4
 
 
 
CD25
 
 
 
 T cells exert immunosuppression by a cell–cell interaction
involving cell surface TGF-
 
 
 
1.
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Introduction
 
In recent years it has become evident that peripheral or
postthymic tolerance is mediated, at least in part, by various
types of regulatory T cells (suppressor T cells) (1). One such
T cell is present in the 5–10% of unstimulated CD4
 
 
 
 T cells
of adult mice that express CD25, the 
 
 
 
-chain of IL-2R.
This became evident from studies by Asano et al., who
showed that thymectomy of certain mouse strains on day 3
of life results in elimination of the CD4
 
 
 
CD25
 
 
 
 T cell sub-
set and the subsequent occurrence of various autoimmune
diseases such as gastritis, orchitis, oophoritis, and thyroiditis
(2). In addition, they showed that reconstitution of such
neonatally thymectomized mice with CD4
 
 
 
CD25
 
 
 
 T cells
prevents the development of these autoimmune diseases (2).
Another subset of CD4
 
 
 
 T cells, CD45RB
 
low
 
 T cells,
has also been found to have immunoregulatory function. In
particular, it was demonstrated that while transfer of
CD4
 
 
 
CD45RB
 
high
 
 T cells into SCID or recombination ac-
tivating gene knockout recipient mice leads to colitis,
transfer of these cells plus CD4
 
 
 
CD45RB
 
low
 
 T cells pre-
vents colitis (3). Interestingly, the regulatory activity of
CD4
 
 
 
CD45RB
 
low
 
 T cells has recently been shown to re-
side in the CD4
 
 
 
CD25
 
 
 
 T cell subpopulation (4), suggest-
ing that T cells regulating gastritis and colitis are similar, if
not the same.
One possible mechanism of the immunosuppression
caused by both CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD45RB
 
low
 
 T
cells is that these cells either secret or cause the secretion of
TGF-
 
 
 
 and/or IL-10. This is suggested by cell transfer
studies of colitis such as those mentioned above, in which it
has been shown that Abs to TGF-
 
 
 
 and/or IL-10R block
suppressor activity of transferred cells (4–6). Also relevant
here are studies showing that orally immunized mice in
whom oral tolerance has been induced manifest T cells that
produce TGF-
 
 
 
1, so-called Th3 T cells, and that T cell
lines that produce IL-10, so-called Tr1 T cells, can prevent
development of colitis in the above described SCID-trans-
fer model (7–9). It should be noted, however, that these
studies of CD4
 
 
 
CD25
 
 
 
 T cells and other types of suppres-
sor T cells in the context of colitis do not correlate with
other studies of CD4
 
 
 
CD25
 
 
 
 T cells. Thus, it has been
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shown repeatedly that when CD4
 
 
 
CD25
 
 
 
 T cells are co-
cultured with CD4
 
 
 
CD25
 
 
 
 T cells in the presence of anti-
CD3 and APCs, CD25
 
 
 
 T cell proliferation is markedly
suppressed, but this suppression depends on an as yet unde-
fined cell–cell interaction and not on humoral factors such
as TGF-
 
 
 
 or IL-10 (10, 11).
In view of this discrepancy, we conducted studies to re-
examine the mechanism of CD4
 
 
 
CD25
 
 
 
 T cell–induced
suppression. Our main findings were that CD4
 
 
 
CD25
 
 
 
 T
cells do produce TGF-
 
 
 
1 and IL-10 when stimulated in an
appropriate fashion and, in addition, express high levels of
TGF-
 
 
 
1 on their cell surfaces. Moreover, CD4
 
 
 
CD25
 
 
 
 T
cells mediate suppression of both T cell and B cell function
which is TGF-
 
 
 
 dependent. Since such suppression re-
quires cell–cell contact, as in prior studies, these data
strongly suggest that CD4
 
 
 
CD25
 
 
 
 T cells mediate immu-
nosuppression via cell surface presentation of TGF-
 
 
 
 to
TGF-
 
 
 
R on target cells.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free, 8-wk-old female Balb/c mice
were purchased from the National Cancer Institute (Frederick,
MD). Animal use adhered to National Institutes of Health Labo-
ratory Animal Care Guidelines.
 
Reagents.
 
Anti-CD3 mAb (145-2C11), anti-CD28 mAb
(37.51), unconjugated and PE-conjugated anti-cytotoxic T lym-
phocyte–associated antigen (CTLA)
 
*
 
-4 mAb (UC10-4F10-11),
Cy-Chrome™–conjugated anti-CD4 mAb (H129.19), biotin-con-
jugated and FITC-conjugated anti-CD25 mAb (7D4), PE-conju-
gated anti-CD25 mAb (PC61), FITC-conjugated, PE-conjugated,
and Cy-Chrome™–conjugated streptavidin, PE-conjugated anti-
CD80 mAb (16-10A1), PE-conjugated anti-CD86 mAb (GL1),
PE-conjugated anti-CD45RB mAb (23G2), PE-conjugated rat
IgG2a, PE-conjugated rat IgG2b, unconjugated and PE-conju-
gated hamster IgG, anti-CD16/CD32 mAb (Fc Block™), PE-
conjugated anti–mouse IL-4 mAb (BVD-1D11), PE-conjugated
anti–mouse IL-10 mAb (JES5-16E3), and rat anti–mouse IL-10R
mAb (1B1.3a) were purchased from BD PharMingen. Anti-FITC
Microbeads, anti-PE Microbeads, and MS
 
 
 
 Separation Columns
were purchased from Miltenyi Biotec. Mouse anti–TGF-
 
 
 
1, -
 
 
 
2,
and -
 
 
 
3 mAb (clone 1D11) was purchased from Genzyme and
R&D Systems. Unconjugated and biotin-conjugated chicken
anti–TGF-
 
 
 
1 Ab, biotin-conjugated goat IgG, biotin-conjugated
goat anti–human latency-associated protein (LAP) of TGF-
 
 
 
1
Ab, normal mouse IgG1, rat anti–mouse IL-10 mAb (clone
JES052A5), and recombinant human latent TGF-
 
 
 
1were pur-
chased from R&D Systems. Recombinant human active TGF-
 
 
 
1
was purchased from R&D Systems and PeproTech. Anti–human
LAP of TGF-
 
 
 
1 mAb (clone 27232.11) was supplied by R&D
Systems. Normal mouse IgG, normal rat IgG, unconjugated and
biotin-conjugated chicken IgY (IgG), and goat anti–mouse IgG
were purchased from Jackson ImmunoResearch Laboratories. Al-
kaline phosphatase–conjugated anti–mouse IgG was purchased
from Pierce Chemical Co. 
 
P
 
-nitro-phenyl phosphate was pur-
chased from Sigma-Aldrich. Methyl-[
 
3
 
H]thymidine was pur-
chased from NEN Life Science Products. Recombinant human
IL-2 was purchased from Life Technologies. Biotin-conjugated
 
rat anti–mouse IgG1 (H143.225.8) was purchased from Southern
Biotechnology Associates, Inc. Horseradish peroxidase–conju-
gated streptavidin was purchased from Zymed Laboratories. Anti-
actin Ab was purchased from Santa Cruz Biotechnology, Inc.
 
Cell Purification.
 
CD4
 
 
 
 T cells were purified using CD4
 
 
 
 T
cell enrichment columns (R&D Systems) from total splenocytes.
CD4
 
 
 
CD25
 
 
 
 T cells were purified by magnetic beads or FACS
 
®
 
sorting. Separation of CD4
 
 
 
CD25
 
 
 
 T cells with magnetic beads
was reported elsewhere (11). In brief, CD4
 
 
 
 T cells were incu-
bated with biotin-conjugated anti-CD25 for 20 min at 4
 
 
 
C,
washed, incubated with FITC-conjugated streptavidin for 15 min
at 4
 
 
 
C, and washed. The cells were then incubated with anti-
FITC Microbeads for 15 min at 4
 
 
 
C and washed. CD25
 
 
 
 cells
were isolated with MS
 
 
 
 positive selection column according to
the manufacturer’s protocol (Miltenyi Biotec). In some experi-
ments, FITC-conjugated anti-CD25 was substituted for biotin-
conjugated anti-CD25 and FITC-conjugated streptavidin. In
some experiments, PE-conjugated anti-CD25 and anti-PE Micro-
beads were used. The magnetically retained cells were shown to
be 
 
 
 
90% CD4
 
 
 
CD25
 
 
 
 cells, and the flow-through were shown
to be 
 
 
 
95% CD4
 
 
 
CD25
 
 
 
 cells by flow cytometric analysis.
For isolation of CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 T cells by
FACS
 
®
 
 sorting, CD4
 
 
 
 T cells were stained with FITC-conju-
gated anti-CD25, or with PE-conjugated anti-CD25 and CD25-
positive and -negative cells were sorted by FACS Vantage™ SE
II (Becton Dickinson). To purify CD25
 
 
 
, CD25
 
 
 
CD45RB
 
low
 
and CD25
 
 
 
CD45RB
 
high
 
 CD4
 
  T cells, CD4  cells were stained
with FITC–anti-CD25 and PE–anti-CD45RB and sorted into
three subpopulations. The purity of each population was  95%.
Cell Culture. The culture medium used in all experiments
was RPMI1640 (Life Technologies) with 10% FCS (Life Tech-
nologies), 100 U/ml penicillin, 100  g/ml Streptomycin, 10
mM Hepes (pH 7.0), 1 mM sodium pyruvate, and 50  M 2-ME
unless mentioned. In some experiments, 1% Nutridoma SP
(Roche Molecular Biochemicals) or 2.5% FCS was used instead
of 10% FCS.
Proliferation Assays. 2.5    104 of CD4 CD25  or CD4 
CD25  T cells were stimulated with plate-bound anti-CD3 mAb
(10  g/ml) with or without soluble anti-CD28 (2  g/ml), and
with or without IL-2 (20 U/ml) in flat-bottom 96-well plates
(0.1 ml). In some experiments, plates were coated with anti-CD3
(10  g/ml), plus either anti–CTLA-4 (15  g/ml) or hamster IgG
(15   g/ml). For coculture of CD25  and CD25  subsets of
CD4  T cells, 2.5   104 of CD4 CD25  or CD4 CD25 , or
both were stimulated with 10  g/ml of soluble anti-CD3 and
5   104 irradiated (3,000 rad) T cell–depleted syngenic spleno-
cytes (non–T cell) in flat-bottom 96-well plates (0.1 ml). Anti–
TGF- , anti–IL-10, anti–IL-10R, or control IgG was added to
the culture. Cells were cultured at 37 C for 72 h and pulsed with
1  Ci of [3H]thymidine for the last 6 h of culture. Then, cells
were harvested and assessed for thymidine incorporation in a liq-
uid scintillation counter.
ELISA for Cytokine Production. CD4 CD25  or CD4 CD25 
T cells were stimulated in a 106/ml concentration with plate-
bound anti-CD3 mAb (10  g/ml) with or without soluble anti-
CD28 (2  g/ml), and with or without IL-2 (20 U/ml) at 37 C.
In some experiments, plates were coated with anti-CD3 (10  g/ml),
plus either anti–CTLA-4 (10  g/ml) or hamster IgG (10  g/ml).
Culture supernatants were collected after 48 h or, in the case of
TGF- 1, after 72 h. Cytokines secreted into culture fluid were
assayed by commercial ELISA kits according to the manufac-
turer’s protocol. IL-10, IL-4, and IFN-  were measured by BD
OptEIA™ ELISA Set (BD PharMingen). For TGF- 1 assay,
*Abbreviations used in this paper: CTLA, cytotoxic T lymphocyte–associ-
ated antigen; LAP, latency associated protein.631 Nakamura et al.
samples were acidified by addition of HCl at 20 mM for 15 min,
neutralized by NaOH, and then TGF- 1 content was measured
by TGF- 1 Emax Immunoassay Kit (Promega) as described pre-
viously (12). Optical densities were measured at 450 nm using a
microplate ELISA reader (MR5000; Dynatech).
Flow Cytometric FACS® Analysis. The expression of CTLA-4
on CD4 CD25  or CD4 CD25  T cells was analyzed as de-
scribed previously (13). In brief, splenocytes were blocked with
anti-CD16/CD32 at 4 C for 15 min, washed and stained with
PE-conjugated anti–CTLA-4 or PE-conjugated control hamster
IgG at 37 C for 2 h. Cells were then stained with FITC-conju-
gated anti-CD25 and Cy-Chrome™-conjugated anti-CD4 at
4 C for 20 min. Cells were washed and analyzed with a FAC-
Scan™ flow cytometer (Becton Dickinson). For analysis of the
expression of CD80 and CD86, purified CD4 CD25  and
CD4 CD25  cells were stimulated separately with anti-CD3, ir-
radiated non–T cells, and IL-2 (20 U/ml) for 72 h. Then, cells
were blocked with anti-CD16/CD32 and stained with Cy-
Chrome™-conjugated anti-CD4 and either of PE-conjugated
anti-CD80 or PE-anti-CD86 at 4 C for 20 min. For staining of
TGF- 1 on the cell surface, unstimulated CD4  T cells, purified
and stimulated CD4 CD25  and CD4 CD25  T cells were
stained with FITC-conjugated anti-CD25, biotin-conjugated
anti-TGF- 1 (or biotin-conjugated chicken IgG for a negative
control), and Cy-Chrome™-conjugated anti-CD4 at 4 C for 30
min, washed and stained with PE-conjugated streptavidin at 4 C
for 15 min. When PE-conjugated Ab was used for cell purifica-
tion, TGF-  was stained with a combination of biotin-conju-
gated anti–TGF- 1 and Cy-Chrome™-conjugated streptavidin.
For the staining with anti-LAP mAb (27232.11), cells were incu-
bated with 27232.11 Ab, washed, incubated with biotin-conju-
gated anti-mouse IgG1, washed, and incubated with PE-conju-
gated streptavidin and Cy-Chrome™–conjugated anti-CD4.
Ig Production. We chose PWM as a stimulator of B cell Ig
production as it is mitogenic for both B cell and T cell, was useful
to measure suppressor activity of human regulatory T cell clones
in our previous study (14) and is applicable also for mouse lym-
phocyte cultures (15). Non–T cells were purified from spleno-
cytes by complement-mediated T cell depletion. 5   104 of
CD4 CD25  cells or CD4 CD25  cells, or both were cocul-
tured with 5   104 non–T cells with 20  g/ml of PWM and 20
U/ml of IL-2 and with or without neutralizing anti-cytokine
(anti–TGF- , anti–IL-10, or control IgG) at 37  C for 8 d. In
some experiments, CD4 CD25  and CD4 CD25  T cells were
mixed at various ratios as indicated. Culture supernatants were
collected and IgG concentration was determined by ELISA: 96-
well ELISA plates (Immulon 1; Dynatech) were coated with 2.5
 g/ml of goat anti–mouse IgG, washed, blocked with 1% BSA/
PBS, and then washed. Standards and samples were put in wells,
incubated at room temperature for 2 h, and washed. Alkaline
phosphatase–labeled anti–mouse IgG was added and incubated at
room temperature for 1 h and washed. Finally, colorimetric sub-
strate p-nitro-phenyl phosphate was added and OD410 was de-
termined using a microplate ELISA reader.
Purification of Membrane Fractions of CD4 CD25  T Cells and
Immunoblot Analysis. To obtain membrane preparation, CD4 
CD25  and CD4 CD25  T cells were isolated from 30 Balb/c
spleens and stimulated with plate-bound anti-CD3 (10  g/ml)
and anti–CTLA-4 (10  g/ml), soluble anti-CD28 (2  g/ml), and
IL-2 (30 U/ml) for 3 d. To obtain total cell lysates, 3   106 cells
were lysed in lysis buffer (1% NP-40, 150 mM NaCl, 20 mM
Tris, pH 7.5, 2 mM EDTA) supplemented with protease inhibi-
tor cocktails (Roche Molecular Biochemicals) for 30 min on ice,
centrifuged at 12,000 g for 30 min at 4 C, and supernatants were
collected. Membrane preparation was performed as described
elsewhere (16). In brief, 2.5   107 cells were collected, washed in
PBS, suspended in relaxation buffer (3 mM NaCl, 100 mM KCl,
3.5 mM MgCl2, 1.25 mM EGTA, 1 mM ATP, 1 mM PMSF, 10
mM Pipes, pH 7.4), sonicated for 10 s three times on ice, and
then centrifuged at 1,000 g for 10 min at 4 C to remove nuclei.
The supernatant was centrifuged over a 10% (wt/vol) sucrose
cushion (100,000 g) for 30 min at 4 C. Cytoplasmic fraction (up-
per layer) was removed and saved, and the membrane pellets
were washed in relaxation buffer, and then solubilized in lysis
buffer.
The lysates were mixed with SDS-sample buffer, incubated at
95 C for 5 min and run in 12% SDS-PAGE at nonreducing con-
dition, and transferred to a nitrocellulose membrane (Hybond™
ECL™; Amersham Pharmacia Biotech). The blotted membrane
was blocked with 5% skim milk/TBS/0.1% Tween 20, washed,
incubated with 0.2  g/ml of biotin-conjugated chicken anti–
TGF- 1 Ab, washed, and incubated with horseradish peroxi-
dase–conjugated streptavidin. Then, the membrane was washed,
developed by SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce Chemical Co.), and exposed to an X-ray film. After
stripping, the membrane was reprobed with anti-actin Ab.
Results
Proliferation and Cytokine Secretion Profile of CD4 CD25 
T Cells. In initial studies, we determined the conditions
resulting in optimal stimulation of CD4 CD25  regulatory
T cells. As shown in Fig. 1 A, CD4 CD25  T cells stimu-
lated by plate-bound anti-CD3 Ab did not proliferate well
whereas CD4 CD25  T cells stimulated with such Ab un-
derwent vigorous proliferation. In contrast, addition of
anti-CD28 Ab (2  g/ml) and/or IL-2 (20 U/ml) to anti-
CD3–stimulated cultures of CD4 CD25  T cells resulted
in proliferation comparable to that of CD4 CD25  T cells
stimulated with anti-CD3 alone or in combination with
anti-CD28 and/or IL-2 (the optimum concentration of
anti-CD28 and IL-2 in these studies had been determined
in preliminary experiments). These results indicate that
consistent with previous findings, CD4 CD25  T cell
proliferation in vitro and, by inference, maintenance of
these cells in vivo are more dependent on CD28 signaling
and IL-2 than are CD4 CD25  T cells (10, 17, 18).
In further studies, we determined the ability of CD4 
CD25  and CD4 CD25  T cells to produce cytokines
under the above established condition of optimal prolifera-
tion. As shown in Fig. 1 B, we found that CD4 CD25  T
cells stimulated by surface-bound anti-CD3 produce low
but detectable amounts of TGF- 1 and such production
was considerably augmented by addition of anti-CD28
and/or IL-2 whereas CD4 CD25  T cells secreted only
minimal amounts of TGF- 1 when stimulated under com-
parable conditions; this was most evident when cells were
stimulated with anti-CD3, anti-CD28, and IL-2, in which
case CD4 CD25  T cells produced about 20 times more
TGF- 1 than CD4 CD25  T cells. In addition, as shown
in Fig. 1 C, we observed that CD4 CD25  T cells also se-
crete high levels of IL-10 when stimulated with anti-CD3,
anti-CD28, and/or IL-2 and again such secretion greatly632 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
exceeded that of CD4 CD25  T cells, in this instance by a
factor of 10. Finally, as shown in Fig. 1, D and E, we found
that CD4 CD25  T cells produce markedly less IL-4 and
IFN-  than CD4 CD25  T cells and were thus neither
Th1 nor Th2 T cells. Taken together, these studies show
for the first time that CD4 CD25  T cells produce high
levels of the regulatory cytokines TGF-  and IL-10 when
appropriately stimulated. As such, they are consistent with
Figure 1. Proliferation and cytokine production of CD4 CD25  regulatory T cells are CD28 and IL-2 dependent. (A) 2.5   104 CD4 CD25  or
CD4 CD25  cells were stimulated with plate-bound anti-CD3 Ab (10  g/ml) with or without soluble anti-CD28 Ab (2  g/ml) and/or exogenous
IL-2 (20 U/ml) in 96-well plates. Cell proliferation was measured by incorporation of [3H]thymidine after 72 h. The results shown represent the mean  
SEM of triplicate wells and representative of three independent experiments. (B–E) 105 CD4 CD25  or CD4 CD25  cells were stimulated with
plate-bound anti-CD3 Ab (10  g/ml) with or without soluble anti-CD28 Ab (2  g/ml) and/or exogenous IL-2 (20 U/ml) in 100  l culture. The
amount of TGF- 1 (B), IL-10 (C), IL-4 (D), and IFN-  (E) in culture supernatant was measured by ELISA. In B, 1% Nutridoma/RPMI was used for
culture media. The results shown represent the mean   SEM of triplicate wells with each well measured in duplicate, and are representative of three in-
dependent experiments. n.d., not detected, *: P   0.00007, **: P   0.0002, ***: P   0.0009, ****: P   0.0008. (F) 105 CD4 CD25  or CD4 CD25 
cells were stimulated with soluble anti-CD3 Ab (10  g/ml), 2   105 irradiated non–T cells and IL-2 (20 U/ml) in 100  l culture. 2.5% FCS/RPMI was
used for culture media and TGF- 1 content in media was subtracted as a background. The results shown represent the mean   SEM of triplicate wells
with each well measured in duplicate, and are representative of three independent experiments.633 Nakamura et al.
previous reports showing a relative abundance of TGF- 
and IL-10 mRNA in CD4 CD25  T cells by reverse tran-
scription (RT)-PCR (2, 11), but contrast with previous re-
ports that show that this cell population secrete low or un-
detectable amounts of TGF-  or IL-10 protein (10, 11). It
should be noted in this context that the high level produc-
tion of TGF-  and IL-10 from a CD4 CD25  T cell is
not simply due to the fact that these cells are memory cells
as CD4 CD25  T cells produce less IL-4 and IFN-  than
CD4 CD25  T cells.
Costimulation through CTLA-4 Enhances Proliferation and
TGF- 1 Production of CD4 CD25  T Cells. Recently,
two groups of investigators reported that suppressor func-
tion of CD4 CD25  T cells are mediated through
CTLA-4 signaling both in vitro and in vivo (4, 13). Fur-
thermore, it has been shown that CTLA-4 is a negative
regulator of T cell responses and crosslinking of CTLA-4
enhances TGF- 1 production by CD4  T cells (14, 19).
These facts prompted us to investigate the involvement of
the CTLA-4 signaling pathway in TGF- 1 production by
CD4 CD25  T cells. In preliminary studies we deter-
mined the expression of CTLA-4 in CD4 CD25  T
cells, both with respect to cell surface and intracellular
CTLA-4, as the majority of CTLA-4 protein resides in
the cytoplasm (20). For this purpose, cells were stained
with anti–CTLA-4 at 37 C rather than 4 C as described
in Materials and Methods. As shown in Fig. 2 A, 43.3% of
CD4 CD25  T cells were positive for CTLA-4 whereas
only 2.8% of CD4 CD25  T cells were similarly positive.
This result is consistent with previous data which demon-
strated abundant expression of CTLA-4 in CD4 CD25 
T cells in comparison with CD4 CD25  T cells (4, 13
17). Next, we determined the effect of anti–CTLA-4
stimulation on CD4 CD25  T cells both with respect to
proliferation and cytokine production. As shown in Fig. 3
A, addition of anti–CTLA-4 to cells stimulated by anti-
CD3 plus anti-CD28 (in the presence or absence of IL-2)
led to enhanced proliferation of CD4 CD25  T cells,
particularly in the presence of exogenous IL-2; in con-
trast, similar CTLA-4 engagement of CD4 CD25  T
cells led to diminished proliferation in the presence and
absence of IL-2. In previous studies it was shown that
cross-linking of CTLA-4 inhibits T cell proliferation in-
duced by the stimulation with anti-CD3 and anti-CD28
(21). The present results show that while this may be true
of mixed CD4 CD25  and CD4 CD25  T cell subpop-
ulations, or CD4 CD25  T cell populations, signaling of
CD4 CD25  T cells through CTLA-4 is a positive stim-
ulus for these T cells. To our knowledge, this is the first
demonstration that CTLA-4 signaling is a positive prolif-
eration stimulus under some conditions. Interestingly,
CD80 and CD86, ligands for CTLA-4 and CD28, are
more strongly expressed on CD4 CD25  T cells than on
CD4 CD25  T cells after stimulation (Fig. 2, B and C).
These results suggest that CD80 and CD86 expressed on
both APCs and on CD4 CD25  T cells can provide co-
stimulatory signals to CD4 CD25  T cells and thus the
latter cells are, in part, autostimulatory.
In additional studies we examined the effect of anti–
CTLA-4 on TGF-  production by CD4 CD25  T cells.
As shown in Fig. 3 B, we found that addition of anti–
CTLA-4 to cultures of T cells stimulated with anti-CD3,
Figure 2. Expression of CTLA-4, CD80, and CD86 on CD4 CD25 
T cells. (A) CTLA-4 on/in splenocytes was stained as described in Mate-
rials and Methods. CD4 CD25  and CD4 CD25  fractions were gated
and expression of CTLA-4 on/in each population is shown. (B and C)
Purified CD4 CD25  and CD4 CD25  T cells were stimulated with
anti-CD3 (10  g/ml), irradiated non–T cells and IL-2 (20 U/ml) for 72 h
and then stained with Cy-chrome™–conjugated anti-CD4 and either of
PE-conjugated anti-CD80 or PE-conjugated anti-CD86. Expression of
CD80 (B) and CD86 (C) in the CD4  gate is shown.634 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
anti-CD28, and IL-2 further enhanced the production of
TGF- 1 by CD4 CD25  T cells whereas such stimula-
tion did not induce substantial TGF- 1 production by
CD4 CD25  T cells. Furthermore, as shown in Fig. 3 C
(and data not shown), this effect of anti–CTLA-4 Ab is
specific for TGF-  production because anti–CTLA-4 Ab
did not augment IL-10, IL-4, or IFN-  production by ei-
ther CD4 CD25  or CD4 CD25  T cells. These data are
consistent with the studies of Chen et al. who demon-
strated that anti–CTLA-4 induces increased TGF- 1 pro-
duction by naive mouse CD4  T cells (19). However, in
the latter case the amount of TGF- 1 produced was con-
siderably lower than that in this study, presumably reflect-
ing the fact that a mixed cell population containing both
CD4 CD25  and CD4 CD25  T cells was being stimu-
lated in the earlier study.
Figure 3. Signaling through CTLA-4 enhances proliferation and
TGF- 1 secretion of CD4 CD25  T cells. (A) 2.5   104 CD4 CD25 
or CD4 CD25  T cells were stimulated with plate-bound anti-CD3
with or without soluble anti-CD28 (2  g/ml), plate-bound anti–CTLA-4,
or exogenous IL-2 (20 U/ml) in 96-well plates. Cell proliferation was
measured by incorporation of [3H]thymidine after 72 h. Plates were
coated either with anti-CD3 (10  g/ml) plus anti–CTLA-4 (15  g/ml)
or anti-CD3 plus hamster IgG (15  g/ml). The results shown are the
mean   SEM of triplicate wells and representative of three independent
experiments. (B and C) 105 CD4 CD25  or CD4 CD25  T cells were
stimulated with plate-bound anti-CD3 Ab, soluble anti-CD28 Ab (2  g/
ml), and exogenous IL-2 (20 U/ml) with or without plate-bound anti–
CTLA-4 in 100  l of culture. The amount of TGF- 1 (B) and IL-10 (C)
was measured by ELISA. In B, 1% Nutridoma/RPMI was used for cul-
ture media. Plates were coated either with anti-CD3 (10  g/ml) plus
anti–CTLA-4 (10  g/ml) or anti-CD3 plus hamster IgG (10  g/ml).
The results shown are the mean   SEM of triplicate wells with each well
measured in duplicate, and are representative of three independent exper-
iments. n.d., not detected, *: P   0.005, **: P   0.00003.635 Nakamura et al.
Suppressor Function of CD4 CD25  T Cells Is Mediated by
TGF- 1. Having established that CD4 CD25  T cells
produce TGF- 1 when appropriately stimulated, we next
investigated whether such production mediates immuno-
suppression. Our approach in these studies was to deter-
mine if CD4 CD25  T cells mediate suppression in the
absence and presence of anti-TGF- . As shown in Fig. 4
A, we observed that in cultures containing control mouse
IgG, CD4 CD25  T cells but not CD4 CD25  T cells
proliferated well in response to stimulation with soluble
anti-CD3 Ab plus irradiated syngenic non–T cells; how-
ever, under this condition, if CD4 CD25  T cells were
cocultured with CD4 CD25  T cells, cell proliferation
was profoundly suppressed. Thus, as previously reported
(10, 11), CD4 CD25  T cells act as suppressor cells. In
contrast, when the same cultures were carried out in cul-
tures containing 50  g/ml of anti–TGF-  (1D11) rather
than mouse IgG, both CD4 CD25  and CD4 CD25  T
Figure 4. Suppression of T cell proliferation by CD4 CD25  regula-
tory T cells is mediated by TGF- . (A and B) 2.5   104 CD4 CD25 
(black bars) or CD4 CD25  T cells (hatched bars), or both (white bars)
were stimulated with soluble anti-CD3 Ab (10  g/ml) and 5   104 of ir-
radiated syngenic non–T cells in 96-well plates in the presence of anti-
cytokine or control IgG. (A) 50  g/ml or 100  g/ml of control mouse
IgG or anti-TGF-  (1D11). (B) 100  g/ml of control rat IgG, anti–IL-
10, or anti–IL-10R. Cell proliferation was measured by incorporation of
[3H]thymidine after 72 h. The results shown are the mean   SEM of
triplicate wells and are representative of four independent experiments.
(C) 2.5   104 CD4 CD25  T cells were stimulated with soluble anti-
CD3 Ab (10  g/ml) and 5   104 of irradiated syngenic non–T cells in
96-well plates in the presence of various amounts of rTGF- 1 (active
form). Cell proliferation was measured by incorporation of [3H]thymidine
after 72 h. The results shown are the mean   SEM of triplicate wells and
are representative of three independent experiments.636 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
cells cultured alone exhibited increased proliferation, and,
more importantly, CD4 CD25  T cell–mediated suppres-
sion was completely abolished. The effect of anti–TGF- 
was dose dependent because addition of the Ab at 100  g/
ml further increased the proliferation of CD4 CD25  T
cells, and consequently, of the coculture of CD4 CD25 
and CD4 CD25  T cells. 25  g/ml of anti–TGF-  only
partially restored cell proliferation (data not shown). Fi-
nally, as shown in Fig. 4 B, although CD4 CD25  T cells
produce large amounts of IL-10, addition of anti–IL-10 or
anti–IL-10R at 100  g/ml to the above cultures did not
decrease the level of CD4 CD25  T cell–mediated sup-
pression. To further confirm that TGF-  is capable of sup-
pressing T cell proliferation under these conditions, we
added various amount of rTGF-  to the cell culture. As
shown in Fig. 4 C, relatively small amount of recombinant
active TGF- 1 (ED50: 31.3–62.5 pg/ml) significantly sup-
pressed cell proliferation of the CD4 CD25  T cells.
These results provide strong evidence that suppression of
T cell proliferation by CD4 CD25  T cells is mediated
by TGF-  and, in addition, the unresponsiveness of
CD4 CD25  T cells to stimulation is due, at least in part,
to autocrine suppression by TGF- .
In further studies we determined if CD4 CD25  T cells
inhibit T cell–dependent Ig synthesis by B cells as well as T
cell proliferation via TGF- . Here we set up cultures of
CD4 CD25  T cells or CD4 CD25  T cells with non–T
cells stimulated with PWM and IL-2 (see Materials and
Methods), and, as shown in Fig. 5 A, demonstrated first
that the CD4 CD25  T cells help B cells produce IgG
whereas CD4 CD25  T cells do not help. We then
showed that addition of CD4 CD25  T cells to cocultures
of CD4 CD25  T cell and non–T cells blocked IgG syn-
thesis in a dose-dependent fashion. Then, as shown in Fig.
5 B, we showed that addition of anti–TGF-  Ab com-
pletely abolished the suppression of CD4 CD25  T cells
in the mixed cell cultures. For this experiment, we used a
polyclonal chicken anti–TGF- 1 Ab because mouse anti–
TGF-  mAb (1D11) used in the studies of T cell prolifera-
tion cross-reacts with mouse IgG in the usual ELISA sys-
tem. According to the manufacturer, this polyclonal
chicken Ab has a similar neutralizing capacity as the mouse
monoclonal anti–TGF-  (1D11). Finally, addition of anti–
IL-10 to cultures did not inhibit the suppression of
CD4 CD25  T cells, but instead decreased IgG produc-
tion, presumably because IL-10 acts as a B cell growth fac-
tor under some conditions (22). From these results, we
conclude that CD4 CD25  T cells also suppress B cell IgG
synthesis via TGF- . These data, however, do not deter-
mine whether TGF-  acts on CD4 CD25  helper T cells
or directly on B cells to mediate suppression.
In that the above experiments show that CD4 CD25 
T cells mediate suppression by TGF- , they suggested that
such suppression does not require cell contact between
CD4 CD25  T cells and their targets. To test this possibil-
ity, we conducted studies using a Transwell™ (Corning)
culture system in which suppressor function was measured
under conditions in which the putative CD4 CD25  sup-
pressor T cells and CD4 CD25  target T cells were sepa-
rated by a membrane. In these studies, CD4 CD25  or
CD4 CD25  T cells were cultured in the inner well in
the presence of soluble anti-CD3 Ab and APCs and
CD4 CD25  “indicator” cells were cultured in the outer
well again in the presence of soluble anti-CD3 and APCs;
then, after 72 h, proliferation of the CD4 CD25  T cells
in the outer well was assessed after transfer to 96-well plates
and addition of [3H]thymidine. Control cultures, in which
only non–T cells were cultivated with anti-CD3 in the in-
Figure 5. CD4 CD25  regulatory T cells suppress B cell Ig synthesis
through TGF- . (A) 5   104 CD4 CD25  or CD4 CD25  T cells, plus
5   104 non–T cells were stimulated with 20  g/ml of PWM and 20
U/ml of IL-2 in 200  l culture. In some wells, CD4 CD25  cells were
added to 5   104 CD4 CD25  cells at the ratio indicated in the figure.
Cells were cultured at 37 C for 8 d and culture supernatant was collected.
The concentration of mouse IgG in the supernatant was determined by
ELISA. The results shown are the mean   SEM of triplicate wells and
are representative of three independent experiments. (B) 5   104
CD4 CD25  (black bars), or 5   104 of both CD4 CD25  and
CD4 CD25  T cells (white bars) were cocultured with 5   104 non–T
cells, and stimulated with 20  g/ml of PWM and 20 U/ml of IL-2 in 200
 l culture. 20  g/ml of control chicken IgG or chicken anti–TGF- 1
Ab, or 100  g/ml of rat anti–IL-10 mAb was added to the culture. Cells
were cultured at 37 C for 8 d and culture supernatant was collected.
Concentration of mouse IgG in the supernatant was determined by
ELISA. The results shown are the mean   SEM of triplicate wells and
representative of three independent experiments.637 Nakamura et al.
ner well, were conducted in parallel. Contrary to expecta-
tion, we found that CD4 CD25  T cells could not medi-
ate suppression of CD4 CD25  T cell proliferation across
a membrane (data not shown). In further studies to deter-
mine if CD4 CD25  T cell–mediated suppression does
not require cell contact we stimulated CD4 CD25  T cells
in the presence of supernatants of culture of CD4 CD25 
T cells stimulated by soluble anti-CD3 and APCs. In paral-
lel with the results of the Transwell™ studies, we found
that the culture supernatant did not suppress CD4 CD25 
T cell proliferation (data not shown). These results are con-
sistent with the previous reports in which CD4 CD25  T
cells failed to suppress T cell proliferation through a mem-
brane (Transwell™ system) or by transfer of their culture
supernatants (10, 11) and suggest that only low, subsup-
pressive amounts of TGF-  are secreted when CD4 
CD25  T cells are stimulated by soluble anti-CD3 and
APCs, the condition under which these cells mediate
suppression. In fact, as shown in Fig. 1 F, we could detect
only small amounts of (latent) TGF- 1 (100–200 pg/106
cells) in the supernatant of CD4 CD25  T cells stimulated
under this condition. This amount is not significantly dif-
ferent from that secreted by CD4 CD25  T cells and is
not sufficient to cause suppression when added to T cell
cultures. Note that the rTGF-  causing suppression in Fig.
4 C is active TGF- .
CD4 CD25  T Cells Express TGF- 1 on Their Cell Sur-
face. The above studies showing that cell contact is necessary
for CD4 CD25  T cell suppression, yet such suppression is
mediated by TGF-  created a paradox that can conceivably
be explained if we assume that suppression is mediated
largely by cell-bound TGF- . In initial studies to explore
this possibility, we stained purified CD4  T cells with
FITC-conjugated anti-CD25 as well as with biotin-conju-
gated polyclonal anti–TGF- 1 and PE-conjugated streptavi-
din. As shown in Fig. 6 A, 15.4% of CD4 CD25  T cells
(1.4% of total CD4  cells) were cell surface TGF- 1 posi-
tive, while virtually no CD4 CD25  T cells were cell
surface TGF- 1 positive. Next, we stained purified
CD4 CD25  and CD4 CD25  T cells after stimulation
Figure 6. CD4 CD25  T cells express TGF- 1 on the cell surface. (A) Enriched CD4  T cells were stained with FITC-conjugated anti-CD25, Cy-
Chrome™–conjugated anti-CD4 and either biotin-conjugated chicken anti–TGF- 1 or biotin-conjugated normal chicken IgG, washed, and stained with
PE-conjugated streptavidin. CD4 CD25  and CD4 CD25  T cells were gated and expression of cell surface-bound TGF- 1 is shown. Thick lines: anti–
TGF- , thin lines: normal chicken IgG. The results shown are the representative of three independent experiments. (B and C) Purified CD4 CD25  and
CD4 CD25  T cells were stimulated with soluble anti-CD3 (10  g/ml) and irradiated non–T cells in the presence of IL-2 (20 U/ml) for 24 h (B) or 6 d
(C). Cells were then stained with Cy-Chrome™–conjugated anti-CD4 and either biotin-conjugated chicken anti–TGF- 1 or biotin-conjugated normal
chicken IgG, washed and stained with PE-conjugated streptavidin. CD4  cells were gated and expression of cell surface-bound TGF- 1 is shown. Thick
lines: anti–TGF- , thin lines: normal chicken IgG. The results shown are the representative of three independent experiments. (D) Graphic representation
of the percentage of surface TGF- 1 positive cells in CD4 CD25  (circle) and CD4 CD25  (triangle) T cells after stimulation.638 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
with soluble anti-CD3, non–T cells, and IL-2. The biotin-
conjugated anti-CD25 Ab was not used for isolation of
CD4 CD25  T cells in this experiment as biotin-conju-
gated anti–TGF-  was used for staining of cells. As shown
in Fig. 6 B, 24 h after stimulation, the expression of TGF-
 1 on CD4 CD25  T cells was dramatically upregulated in
that 64% of the cells were now surface TGF-  positive.
While some CD4 CD25  T cells also expressed TGF- 1
on the cell surface after such stimulation (13%), in this case
both the extent and intensity of staining was far below that
of CD4 CD25  T cells. Finally, as shown in Fig. 6 C, 6 d
after stimulation CD4 CD25  T cells still manifested a high
level of surface TGF- 1, whereas the level of surface TGF-
 1 on CD4 CD25  T cells had fallen to baseline. These
results are summarized in the time course study in Fig. 6
D where it is shown that TGF- 1 expression on
CD4 CD25  and CD4 CD25  T cells after stimulation
was quite different: the percentage of surface TGF- 1–posi-
tive cells in the CD4 CD25  T cell subset increased from
15 to 64% in 24 h, reached a peak of 77% on day 3, and
then maintained the level up to day 6. In contrast, the per-
centage of TGF- 1–bearing CD4 CD25  T cells attained a
peak of 29% on day 2 and then rapidly decreased to baseline.
We also isolated CD4 CD25  T cells using another anti-
CD25 mAb (PC61) and stained cell surface–bound TGF- 
after stimulation, which resulted in virtually identical stain-
ing pattern as the experiments shown above in which cells
were isolated using anti-CD25 (7D4) (data not shown). Cell
surface TGF-  was also observed when CD4 CD25  T
cells were stimulated with anti-CD3 and APCs in the ab-
sence of exogenous IL-2 for 24 h but the expression level
was lower than those stimulated with IL-2 (data not shown),
suggesting that IL-2 is not necessary for the surface expres-
sion of TGF- 1 by these cells, but does enhances such ex-
pression. Finally, incubation of the polyclonal anti–TGF- 1
Ab with rTGF- 1 before the staining of CD4 CD25  T
cells significantly decreased the fluorescence intensity of the
surface TGF-  staining (data not shown).
Anti–TGF-  used in the above studies to detect cell sur-
face TGF-  is a polyclonal (chicken) Ab raised against re-
combinant active (human) TGF- 1 and purified by TGF-
 1 affinity chromatography; thus epitopes recognized by
this Ab reside in active TGF- 1. To determine if latent
TGF- 1 is in fact present on the cell surface, we also
stained cells with Abs specific for LAP of TGF- 1. As
shown in Fig. 7 A, we observed high levels of LAP ex-
pressed on the cell surface of stimulated CD4 CD25  T
cells using an anti-LAP mAb (clone 27232.11 [R&D Sys-
tems]) but only small amounts of LAP on the surface of
stimulated CD4 CD25  T cells. Similar results were ob-
tained with a polyclonal goat anti-LAP Ab (R&D Systems;
data not shown). Finally, as shown in Fig. 7, B and C, in
contrast to the positive staining obtained with anti–TGF- 
Ab or anti-LAP Abs, staining with anti–IL-10 or anti–IL-4
Abs for surface IL-10 or IL-4 was negative.
To further confirm that CD4 CD25  T cells express
high levels of TGF- , we conducted immunoblot analy-
ses. First, we purified total cell lysate from activated
CD4 CD25 , CD4 CD25  and whole CD4  T cells and
analyzed the lysates for TGF-  content. As shown in Fig. 8
A, TGF- 1 band was detected only in the CD4 CD25  T
cell lysate but not in CD4 CD25  or CD4  lysates. Lysate
from 3   106 CD4 CD25  T cells and 2 ng rTGF- 1 gave
Figure 7. CD4 CD25  T cells express LAP of TGF- 1 but not IL-10
or IL-4 on the cell surface. Purified CD4 CD25  and CD4 CD25  T
cells were stimulated with soluble anti-CD3 (10  g/ml) and irradiated
non–T cells in the presence of IL-2 (20 U/ml) for 24 h. Cells were incu-
bated with Cy-Chrome™–conjugated anti-CD4 and either anti-LAP
mAB (27232.11) (A), PE-conjugated anti–IL-10 (B), or PE-conjugated
anti–IL-4 (C). Incubation with isotype-matched control IgG for each anti-
cytokine was performed in parallel. In panel A, after incubation with anti-
LAP, cells were washed, incubated with biotin-conjugated anti–mouse
IgG1, washed, and incubated with PE-conjugated streptavidin. CD4 
cells were gated and expression of LAP (A), IL-10 (B), and IL-4 (C) on
the cell surface was shown. Thick lines: anti-cytokine; thin lines: isotype-
matched control IgG.639 Nakamura et al.
almost identical density of TGF-  band in this assay (data
not shown). Reprobing the same membrane with anti-actin
Ab revealed bands of actin with almost identical intensity in
each sample, showing that almost equal amount of protein
had been loaded in each lane. Next, to confirm that TGF- 
expressed by CD4 CD25  T cells exists on the cell surface,
we obtained purified membrane fraction of activated
CD4 CD25  and CD4 CD25  T cells (see Materials and
Methods). As shown in Fig. 8 B, the TGF-  band was de-
tected only in the membrane fraction of CD4 CD25  T
cells, but not in the membrane fraction of CD4 CD25  or
cytoplasmic protein fraction of either cell population.
In further studies we sought to verify that the surface
TGF- 1 associated with CD4 CD25  T cells arises from
the cell itself and not from an exogenous source such as
APCs in the culture or FCS in the culture medium. To this
end, we stimulated purified CD4 CD25  or CD4 CD25 
T cells with plate-bound anti-CD3, soluble anti-CD28,
plate-bound anti-CTLA-4, and IL-2 for 24 h in the pres-
ence of 1% Nutridoma/RPMI medium (rather than FCS/
RPMI) without addition of APCs and then determined cell
surface expression of TGF- 1 with the staining procedure
described above. As shown in Fig. 9 A, we found that
73.4% of CD4 CD25  T cells expressed TGF- 1 on the
cell surface whereas only 8.5% of CD4 CD25  T cells ex-
pressed cell surface TGF- 1. As the only possible source of
TGF- 1 in these cultures was the T cells themselves,
we concluded that TGF- 1 detected on the surface of
CD4 CD25  T cells was produced by these cells and did
not arise from an exogenous source.
As shown in Fig. 3 B and Fig. 9 A, CD4 CD25  T cells
stimulated by plate-bound anti-CD3, soluble anti-CD28,
plate-bound anti–CTLA-4, and IL-2 secret high levels of
TGF- 1, indicating that these cells can produce both sur-
face and secreted TGF- 1 when maximally stimulated. In
addition, CD4 CD25  T cells stimulated under these con-
ditions express higher levels of surface-bound TGF- 1
than those stimulated with soluble anti-CD3, non–T cells,
and IL-2 (Fig. 9 B); this allows us to determine if higher
level of TGF- 1 expression is associated with enhanced
suppressor activity. To this end, purified CD4 CD25  T
cells were stimulated with soluble anti-CD3, non–T cells
and IL-2 (stimulation condition 1), or with plate-bound
anti-CD3, soluble anti-CD28, plate-bound anti-CTLA-4,
and IL-2 (stimulation condition 2) for 4 d, irradiated (1,000
rad) to inhibit cell proliferation, and then mixed with
freshly isolated CD4  T cells at 1:1 ratio to form cultures
that were stimulated with anti-CD3 and non–T cells. We
found that CD4 CD25  T cells stimulated by stimulation
condition 2 suppressed CD4  T cell proliferation more
profoundly than those stimulated by stimulation condition
1 when assessed by [3H]thymidine incorporation (Fig. 9 C).
Mixtures of stimulated CD4 CD25  T cells with fresh
CD4  T cells at 1:2 ratio gave almost the same results (data
not shown).
CD4 CD25  Population but Not CD4 CD25 CD45RBlow
Population Expresses High Levels of TGF- . In the experi-
ments shown above, we compared CD4 CD25  T cells
and CD4 CD25  T cells and showed that the former pop-
ulation is a high expresser of cell surface–bound and se-
creted TGF- 1. To exclude the possibility that this is sim-
ply because CD4 CD25  T cells have been subject to
prior stimulation through the TCR and that high level
expression of TGF-  is simply a feature of previously stim-
ulated T cells, we purified CD25 , CD25 CD45RBlow,
and CD25 CD45RBhigh populations of CD4  T cells. As
reported previously (10, 11, 23), most of the CD4 CD25 
population was CD45RBlow (data not shown). As shown
in Fig. 10 A, stimulated CD4 CD25  T cells expressed
abundant cell surface-bound TGF- , whereas stimulated
CD25  CD45RBlow and CD25 CD45RBhigh T cells ex-
pressed only small amount of cell surface–bound TGF- 1.
In addition, as shown in Fig. 10 B, CD4 CD25  T cells
also secreted significantly higher amount of TGF- 1
Figure 8. Immunoblot analyses for the expression of TGF- 1 in
CD4 CD25  T cells. (A) Total cell lysates purified from 3   106 of ac-
tivated CD4 CD25 , CD4 CD25  and CD4  T cells were run in
SDS/PAGE and blotted to the membrane. 5 ng of active and latent
rTGF- 1 were loaded in parallel to serve as positive controls. Membrane
was first probed using chicken anti–TGF- 1, stripped, and reprobed
with anti-actin Ab. (B) Lysates from membrane (derived from 2.5   107
cells) and cytoplasmic (derived from 1.25   107 cells) preparations of ac-
tivated CD4 CD25  and CD4 CD25  T cells were subjected to SDS/
PAGE and immunoblot analysis. Membrane was probed using chicken
anti–TGF- 1.640 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
into the culture supernatant after stimulation than
CD25 CD45RBlow and CD25 CD45RBhigh populations.
In contrast, as shown in Fig. 10, C–E, CD25 CD45RBlow
T cells secreted huge amounts of IL-10, IL-4, and IFN- 
which far exceeded that produced by CD25  and CD25 
CD45RBhigh T cells. Finally, while CD4 CD25  T cells
did not produce high levels of IL-4 or IFN- , they did
produce quite high amount of IL-10, albeit at levels signifi-
cantly lower than that of CD4 CD25 CD45RBlow T cells.
Taken together, these data show that the expression of
high levels of TGF-  in both membrane-bound and sol-
uble forms is a unique feature of CD4 CD25  regulatory
T cells.
From these results relating to surface TGF- 1 expression
on CD4 CD25  T cells, together with those relating
to the twin observations that anti–TGF-  abolishes
CD4 CD25  T cell-mediated immunosuppression on T
cell proliferation and B cell Ig synthesis and that such sup-
pression requires cell–cell contact, we conclude that
CD4 CD25  T cells mediate immunosuppression via the
expression of surface-bound TGF- 1.
Discussion
In this study we provide data showing that stimulated
CD4 CD25  T cells are a preferential source of TGF- 1,
Figure 9. Expression of surface TGF- 1 after the stimulation with
plate-bound anti-CD3 and anti–CTLA-4, soluble anti-CD28, and IL-2.
(A) Purified CD4 CD25  and CD4 CD25  T cells were stimulated
with plate-bound anti-CD3 (10  g/ml) and anti–CTLA-4 (10  g/ml),
soluble anti-CD28 (2  g/ml), and IL-2 (20 U/ml). Cultures were carried
out in 1% Nutridoma/RPMI. 24 h later, cells were incubated with Cy-
Chrome™–conjugated anti-CD4 and either biotin-conjugated chicken
anti–TGF- 1 or biotin-conjugated normal chicken IgG, washed, and
stained with PE-conjugated streptavidin. CD4  cells were gated and ex-
pression of cell surface-bound TGF- 1 is shown. Thick lines: anti–TGF- ;
thin lines: normal chicken IgG. (B) Purified CD4 CD25  T cells were
stimulated with soluble anti-CD3 (10  g/ml), non–T cells and IL-2
(20 U/ml) (left panel), or with plate-bound anti-CD3 (10  g/ml) and
anti–CTLA-4 (10  g/ml), soluble anti-CD28 (2  g/ml), and IL-2 (20
U/ml) (right panel). 60 h later, cells were incubated with Cy-Chrome™–
conjugated anti-CD4 and either biotin-conjugated chicken anti–TGF- 1
or biotin-conjugated normal chicken IgG, washed, and stained with PE-
conjugated streptavidin. CD4  cells were gated and expression of cell sur-
face-bound TGF- 1 is shown. Thick lines: anti–TGF- ; thin lines: nor-
mal chicken IgG. (C) Purified CD4 CD25  T cells were stimulated with
soluble anti-CD3 (10  g/ml), non–T cells and IL-2 (20 U/ml) (condi-
tion 1) or with plate-bound anti-CD3 (10  g/ml) and anti–CTLA-4 (10
 g/ml), soluble anti-CD28 (2  g/ml), and IL-2 (20 U/ml) (condition 2)
for 4 d and irradiated (1,000 rad). 2.5   104 CD4  T cells were mixed
with 2.5   104 CD4 CD25  T cells stimulated in condition 1 or condi-
tion 2, and stimulated with soluble anti-CD3 Ab (10  g/ml) and 5   104
of irradiated syngenic non–T cells in 96-well plates. Cell proliferation was
measured by incorporation of [3H]thymidine after 72 h. The results
shown are the mean   SEM of triplicate wells and are representative of
two independent experiments.641 Nakamura et al.
producing both surface-bound and secreted TGF- 1 un-
der certain conditions, and mainly surface-bound TGF- 1
under others. The production of secreted TGF- 1 occurs
when these cells are stimulated with plate-bound anti-
CD3 and is enhanced by signaling via CD28, IL-2R, and
CTLA-4, i.e., “maximal” stimulation conditions that may
occur in vivo only in the presence of an intense immune
response. In contrast, the production of surface-bound
TGF-  (associated with the secretion of modest amounts
of TGF- 1) occurs in the presence of “ordinary” levels of
stimulation by APCs. Nevertheless, these latter levels of
stimulation support the TGF- 1–mediated suppressor
function of CD4 CD25  T cells with respect to T cell
proliferation and B cell Ig production in vitro, as in both
cases suppression can be observed under these conditions
which is inhibited by anti–TGF- . These findings, plus
the observation that suppression requires cell–cell contact,
lead us to the conclusion that CD4 CD25  T cell–medi-
ated immunosuppression is mediated by cell surface–
bound TGF- 1. Whether CD4 CD25  T cells that both
express cell surface–bound TGF- 1 and secrete TGF- 1
mediating suppression occur in vivo await further studies.
In either case, it now becomes clear that autoimmune
mouse models characterized by CD4 CD25  T cell de-
pletion such as mice thymectomized in the neonatal pe-
riod and nude mouse recipients of syngenic CD25  cell–
depleted splenocytes develop autoantibodies because of
the absence of suppressor T cells producing TGF- 1 (2,
24). In addition, mice with a conditioned knockout of
TGF- R type II gene, in which receptor signaling is inac-
tivated in a B cell–specific manner, develop anti-double
stranded DNA autoantibodies because of the lack of abil-
ity to respond to suppressor T cells producing TGF- 
(25).
Figure 10. Comparison of
cytokine expression among
CD25 , CD25 CD45RBlow and
CD25 CD45RBhigh popula-
tions of CD4  T cells. (A)
Purified CD4 CD25 ,
CD4 CD25   CD45RBlow and
CD4 CD25 CD45RBhigh T
cells were stimulated with plate-
bound anti-CD3 (10  g/ml) and
anti–CTLA-4 (10  g/ml), solu-
ble anti-CD28 (2  g/ml), and
IL-2 (20 U/ml). 24 h later, cells
were incubated with either bi-
otin-conjugated chicken anti–
TGF- 1 or biotin-conjugated
normal chicken Ig G, washed, and
stained with Cy-Chrome™–con-
jugated streptavidin. Expression of
cell surface–bound TGF- 1 is
shown. Thick lines: anti–TGF- ;
thin lines: normal chicken IgG.
(B–E) 105 CD4  CD25 , CD4 
CD25 CD45RBlow and CD4 
CD25 CD45RBhigh T cells were
stimulated with plate-bound anti-
CD3 (10  g/ml) and anti–
CTLA-4 (10  g/ml), soluble
anti-CD28 (2  g/ml) and IL-2
(20 U/ml) in 100  l culture for
72 h. The amount of TGF- 1
(B), IL-10 (C), IL-4 (D), and
IFN-  (E) in culture supernatant
was measured by ELISA. In B,
1% Nutridoma/RPMI was used
for culture media. The results
shown represent the mean  
SEM of triplicate wells with each
well measured in duplicate. n.d.,
not detected.642 CD4 CD25  Mediates Cell Contact Immunosuppression via Cell Surface TGF- 
Thornton and Shevach reported that after stimulation,
CD4 CD25  T cells exhibit more potent suppressor func-
tion without an additional stimulation through TCR in an
antigen nonspecific manner (26). Our time course study of
cell surface TGF- 1 is consistent with their findings, as the
expression of cell surface TGF- 1 on CD4 CD25  T cells
reaches a peak on day 3 poststimulation, and maintains a
similar level of TGF- 1 expression for at least 6 d after
stimulation; thus, as previously stimulated CD4 CD25  T
cells already express cell surface TGF- 1, they do not have
to be re-stimulated to mediate suppression. Furthermore,
inasmuch as CD4 CD25  T cells maintain high levels of
cell surface TGF- 1 for quite a long time, it is understand-
able that previously stimulated CD4 CD25  T cells possess
stronger suppressor function than unstimulated cells. This
follows from the fact that previously stimulated CD4 
CD25  T cells can immediately initiate suppression
whereas resting CD4 CD25  T cells require some time af-
ter stimulation through TCR to express surface TGF- 1
and mediate suppression.
As alluded above, previous studies of CD4 CD25  T
cell suppressor function have provided data contrary to
those presented here in that they suggest that CD4 CD25 
T cells do not produce substantial amount of TGF-  and
suppression mediated by such cells is not mediated by
TGF-  (2, 10, 11). The question therefore arises as to why
the present studies are in disagreement with these previous
studies. We believe that the answer lies in the fact that
CD4 CD25  T cells only produce high, easily detectable
amount of TGF-  when maximally stimulated (by plate-
bound anti-CD3, soluble anti-CD28, or IL-2 plus anti–
CTLA-4). In contrast, when they are stimulated by soluble
anti-CD3 and APCs, i.e., conditions usually used to mea-
sure suppressor activity, they secrete relatively low amounts
of TGF- , yet express surface-bound TGF- . Given the
fact that soluble TGF- 1 is not readily detectable in cul-
tures under these latter conditions, and moreover, the sup-
pression requires cell–cell contact, it was understandably
concluded that suppression was not mediated by TGF- 1.
This conclusion, however, is unwarranted given the fact
that CD4 CD25  T cells express surface-bound TGF- 
and that suppression is abolished by anti–TGF- .
A second and related question that also needs explana-
tion is why anti–TGF-  Ab did not reverse CD4 CD25 
T cell–mediated suppression in previous studies (10, 11).
One possibility (one that we favor) relates to the biology of
TGF- –mediated suppressor function. It is known that
TGF-  is produced in a latent (inactive) form comprised of
the active molecule encased in LAP and must be converted
to an active form, TGF- 1 unassociated with LAP, to ex-
press biological activity. Although the mechanism of acti-
vation of latent TGF-  is not yet fully understood, recent
evidence suggests that it requires binding to one or another
protein on the cell surface. For instance, it may interact
with thrombospondin-1, one of the major activators of
TGF- 1 (27) and the complex thus formed then interacts
with CD36 on macrophages (28) or possibly with CD47
on T cells (29); to form a complex that allow plasmin to
strip off LAP from latent TGF-  and convert the latter to
active TGF-  (28). Another possible binding molecule on
the cell surface is  v 6 integrin which interacts with LAP
to facilitate a conformational change of the latter protein
which allows the exposure of active TGF-  (30). Our
demonstration that LAP as well as TGF- 1 exists on the
cell surface suggests that TGF- 1 bound to the cell surface
is present as latent TGF- 1 which is activated upon cell–
cell contact to mediate CD4 CD25  T cell suppression. In
this situation, it is difficult to inhibit TGF- 1–mediated
suppression with anti-TGF- , as the latter must interact
with TGF- 1 in the short period between its conversion to
an active form and its interaction with a relevant TGF- R
at a relatively protected site on the cell surface. In the
present situation this roadblock to the identification of
TGF-  production as the inhibiting mechanism was over-
come by the fact that high concentrations of high affinity
anti–TGF-  Ab were used in the inhibition studies that
could presumably act even at the cell surface to inhibit
TGF-  –mediated suppression.
A final question relates to whether CD4 CD25  T cell
suppression is mediated by TGF-  alone or whether other
mechanisms may also play a role under some circum-
stances. First, with regard to possible effects of a second
suppressor factor, IL-10, we have shown here that while
addition of anti–TGF-  Ab to cultures results in reversal of
suppression, addition of anti–IL-10 or anti–IL-10R Ab
does not. Despite these results, it is still possible that IL-10
contributes to the suppressive effect. This view comes from
recent studies showing that even though TGF-  and not
IL-10 is the proximal cause of negative regulation resulting
from feeding antigen (i.e., induction of oral tolerance),
nevertheless the presence of IL-10 is necessary to downreg-
ulate IL-12/IFN-  production which would otherwise in-
hibit expansion/proliferation of TGF- –producing cells
(31). Thus, in the in vitro system studied here where high
levels of IL-12/IFN-  are not present, IL-10 seems irrele-
vant, but in in vivo situations where high levels of the IL-
12/IFN-  are present, it may be highly relevant.
The mechanism by which TGF- 1 is retained on the
surface of CD4 CD25  T cells and becomes activated is
presently unknown. TGF- 1 found on the surface of mac-
rophages is bound to thrombospondin-1, and the latter, in
turn, interacts with a cell surface molecule, CD36 (28).
Thus, it is likely that TGF- 1 is retained on the surface of
CD4 CD25  T cells by binding to certain as yet unidenti-
fied surface molecules. Inasmuch as the surface-bound
TGF-  was detected by Abs whose target epitopes reside
in both active TGF-  and LAP, it is likely that surface
TGF- 1–positive CD4 CD25  T cells bind functionally
inactive TGF- 1 still associated with LAP. Then, upon
cell–cell contact with a potential target cell, cell surface
LAP is stripped away and functionally active TGF- 1 be-
comes available for suppression. This would imply that a
proteolytic mechanism associated with the CD4 CD25  T
cell or its target becomes activated at this point. Another
possibility not mutually exclusive with the idea that cell
surface TGF- 1 is present associated with LAP, is that643 Nakamura et al.
TGF-  on the cell surface binds to a TGF- R. If this is so,
however, it is likely that the receptor does not transduce a
TGF-  signal (such as TGF- R type III), as TGF-  is de-
monstrably retained on the cell surface of quite a long time
without affecting cell function.
Although TGF-  could be stained with three different
Abs, chicken anti-TGF- 1, mouse anti-LAP mAb, and
goat anti-LAP polyclonal Ab, we could not observe posi-
tive staining using anti–TGF-  mAb, 1D11, which was
used for neutralization of TGF- . 1D11 anti–TGF- 
mAb was raised against bovine TGF- 2 and reacts with
active form of TGF- 1,  2, and  3, but not with latent
TGF-  (27). Thus, if cell surface TGF-  exists in a latent
form, the epitope recognized by 1D11 may be hidden by
LAP. If surface TGF-  binds to some TGF- R, again the
epitope will be masked by the interaction between TGF- 
and its receptor.
CTLA-4 signaling significantly enhanced the prolifera-
tion of CD4 CD25  T cells induced by anti-CD3 and
anti-CD28. At first glance this seems paradoxical as CTLA-4
engagement also enhances the production of TGF- , a
proliferation inhibitor. Indeed, CD4 CD25  T cells are
unresponsive to the stimulation with soluble anti-CD3 and
APCs, which is at least in part due to the expression of
TGF- , as proliferation was partially restored by anti–
TGF-  Ab. It should be noted, however, that when these
cells are stimulated with plate-bound anti-CD3 and solu-
ble anti-CD28, they proliferate to the same degree as
CD4 CD25  T cells, and addition of active rTGF- 1 to
such culture does not suppress T cell proliferation signifi-
cantly (data not shown). Thus, the sensitivity of T cell pro-
liferation to TGF- –mediated suppression is dependent on
the condition of T cell stimulation. Finally, CD4 CD25 
T cell proliferation induced by plate-bound anti-CD3 and
soluble anti-CD28 is also resistant to TGF- –mediated
suppression, whereas low amount of TGF-  leads to dra-
matic suppression of T cell proliferation stimulated with
soluble anti-CD3 and APCs. Taken with the observation
that CD4 CD25  T cell proliferation stimulated with
plate-bound anti-CD3 is not suppressed by CD4 CD25 
T cells (11), these data relating to TGF- –mediated sup-
pression are in line with our conclusion that TGF-  medi-
ates suppression of CD4 CD25  T cells.
In future studies it will be important to demonstrate that
production of TGF-  by CD4 CD25  suppressor T cells
also explain the regulatory activity of these cells in vivo as
well as in vitro. In studies alluded to above, Powrie et al.
have shown that CD4 CD25  T cells mediate suppression
of colitis in the SCID transfer models of colitis and, in ad-
dition, this suppression requires the presence of TGF-  (4,
5). The present studies suggest that these cells are, in fact
the source of the TGF- , but further in vivo studies will be
necessary to prove this point.
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